Literature DB >> 33902275

Engineered Conotoxin Differentially Blocks and Discriminates Rat and Human α7 Nicotinic Acetylcholine Receptors.

Shuai Wang1, Xiaopeng Zhu1,2, Manqi Zhangsun1, Yong Wu2, Jinpeng Yu2, Peta J Harvey3, Quentin Kaas3, Dongting Zhangsun1,2, David J Craik3, Sulan Luo1,2.   

Abstract

The α7 nicotinic acetylcholine receptor (nAChR) is present in the central nervous system and plays an important role in cognitive function and memory. α-Conotoxin LvIB, identified from genomic DNA of Conus lividus, its three isomers and four globular isomer analogues were synthesized and screened at a wide range of nAChR subtypes. One of the analogues, amidated [Q1G,ΔR14]LvIB, was found to be a potent blocker of rat α7 nAChRs. Importantly, it differentiates between α7 nAChRs of human (IC50: 1570 nM) and rat (IC50: 97 nM). Substitutions between rat and human α7 nAChRs at three key mutation sites revealed that no single mutant could completely change the activity profile of amidated [Q1G,ΔR14]LvIB. Rather, we found that the combined influence of Gln141, Asn184, and Lys186 determines the α7 nAChR species specificity of this peptide. This engineered α4/4 conotoxin has potential applications as a template for designing ligands to selectively block human α7 nAChRs.

Entities:  

Year:  2021        PMID: 33902275     DOI: 10.1021/acs.jmedchem.0c02079

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Marine Origin Ligands of Nicotinic Receptors: Low Molecular Compounds, Peptides and Proteins for Fundamental Research and Practical Applications.

Authors:  Igor Kasheverov; Denis Kudryavtsev; Irina Shelukhina; Georgy Nikolaev; Yuri Utkin; Victor Tsetlin
Journal:  Biomolecules       Date:  2022-01-23

2.  Characterization of an α 4/7-Conotoxin LvIF from Conus lividus That Selectively Blocks α3β2 Nicotinic Acetylcholine Receptor.

Authors:  Man Guo; Jinpeng Yu; Xiaopeng Zhu; Dongting Zhangsun; Sulan Luo
Journal:  Mar Drugs       Date:  2021-07-17       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.